INTRODUCTION Products containing anthraquinones (AQ) are mainly used as laxatives and have several biological effects. Long-term use of AQ laxatives is associated with an increased risk of serious adverse events (AEs), such as colorectal cancer (CRC). We will systematically synthesize the evidence on the potential association between the use of AQ laxatives and the risk of CRC. METHODS AND ANALYSIS We will search MEDLINE, Embase, Scopus, the Cochrane Library, Google Scholar, and Clinicaltrials.gov. To avoid missing any relevant studies, we will search the bibliographies of retrieved papers and recent reviews in the field. Interventions will include products containing oral AQ laxatives, in particular, those derived from rhubarb, senna, cascara, buckhorn, and aloe. Two review authors will independently screen title, abstract, and full texts and will independently extract data from included studies. The primary outcome is the number of participants diagnosed with CRC, while the secondary outcome will be cases of melanosis coli. We will also consider all other AEs reported in the included studies, in particular, intestinal bleeding, alterations of gastrointestinal motility, and potential for dependence. When possible and appropriate, for each outcome, a meta-analysis will be performed. DISCUSSION This protocol is prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines. The protocol gives an insight into the scope and parameters for the systematic review to be carried out. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42019125414.

中文翻译：

---

蒽醌泻药与结直肠癌之间的关联：系统评价和荟萃分析方案。

简介 含有蒽醌 (AQ) 的产品主要用作泻药，具有多种生物效应。长期使用 AQ 泻药会增加结直肠癌 (CRC) 等严重不良事件 (AE) 的风险。我们将系统地综合关于使用 AQ 泻药与结直肠癌风险之间潜在关联的证据。方法和分析 我们将搜索 MEDLINE、Embase、Scopus、Cochrane 图书馆、Google Scholar 和 ClinicalTrials.gov。为了避免错过任何相关研究，我们将检索检索到的论文的参考书目和该领域的最新评论。干预措施将包括含有口服 AQ 泻药的产品，特别是源自大黄、番泻叶、鼠李皮、鹿角和芦荟的产品。两位综述作者将独立筛选标题、摘要和全文，并独立从纳入的研究中提取数据。主要结果是诊断患有结直肠癌的参与者人数，次要结果是大肠杆菌黑变病病例。我们还将考虑纳入研究中报告的所有其他不良事件，特别是肠道出血、胃肠动力改变和潜在的依赖性。在可能且适当的情况下，将对每个结果进行荟萃分析。讨论 本协议是根据系统评价和荟萃分析协议指南的首选报告项目编写的。该协议深入了解了要进行的系统审查的范围和参数。系统审查注册 PROSPERO CRD42019125414。